The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

A recent study involving nearly 50,000 individuals provided strong evidence that eradicating Helicobacter pylori (H. pylori) ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

ADRX-0405 is uniquely being tested during its 1a/b clinical trials. ADRX-0405 is labeled as a STEAP1 ADC (primarily ...

An Australian woman who kept ignoring severe tummy aches, thinking they were due to some food intolerance, was ultimately ...

Persistent pain in areas like the back, abdomen, head, bones, or chest could signal underlying health issues, including ...